High cholesterol is one of the most common chronic conditions worldwide. Around half of all adults have cholesterol levels that their doctor would want to improve — yet many people have no idea, because raised cholesterol rarely causes noticeable symptoms. Left unmanaged, it quietly promotes the build-up of fatty plaques in blood vessel walls, raising the risk of heart attack and stroke over the years.

That makes it genuinely good news that the latest generation of weight-loss medications — GLP-1 receptor agonists — don't just help with weight. They also improve the full lipid profile directly, and the evidence is now robust across multiple large clinical trials.

What is cholesterol, and which types are there?

Cholesterol is a fatty substance that travels through the bloodstream bound to transport proteins called lipoproteins. The key types are:

Together, these three measurements make up your "lipid profile," which your doctor uses to assess your overall cardiovascular risk.

Do GLP-1 medications improve cholesterol?

Yes — and the evidence is clear across multiple major studies. The headline figures look like this:

The triglyceride reduction is particularly striking. A drop of 20–28% is comparable to what you'd expect from dedicated triglyceride-lowering drugs such as fibrates. For the many people with obesity or type 2 diabetes who have elevated triglycerides, this is an important bonus on top of the weight-loss benefit.

The mechanisms behind the lipid effect

Why do GLP-1 medications improve cholesterol? Several mechanisms work simultaneously:

Weight loss

The most straightforward reason: when you lose weight, your body burns fat and produces fewer triglycerides. Visceral fat — the fat stored around internal organs — is a major source of VLDL particles, which are converted to LDL in the bloodstream. Less visceral fat means fewer VLDL particles and therefore lower LDL and triglyceride levels.

Direct suppression of hepatic VLDL production

GLP-1 receptors are present in liver cells. When these receptors are activated, the liver's production of VLDL (Very Low-Density Lipoprotein) — the triglyceride-rich particles that are precursors to LDL — is reduced. This effect occurs independently of weight loss and is likely one reason why the triglyceride reduction is so pronounced.

Improved insulin sensitivity

Insulin resistance — very common in people with obesity — drives the overproduction of triglycerides and VLDL by the liver. When GLP-1 medications improve insulin sensitivity, this signal weakens, and the liver produces fewer triglyceride-rich lipoproteins.

Slower gastric emptying reduces fat absorption

GLP-1 slows the rate at which food leaves the stomach, meaning dietary fat is absorbed more gradually in the gut. This slower absorption reduces the sharp post-meal spikes in triglycerides that are damaging to blood vessels over time.

What do the major studies show?

STEP 1 (semaglutide 2.4 mg)

The STEP 1 trial — published by Wilding et al. in the New England Journal of Medicine in 2021 — is the landmark randomised controlled trial for semaglutide 2.4 mg as a weight-loss treatment. Over 68 weeks with 1,961 participants, it showed:

Average body weight fell by 14.9% — and the lipid improvements were clearly present beyond what weight loss alone could explain.

SURMOUNT-1 (tirzepatide)

The SURMOUNT-1 trial — published by Jastreboff et al. in the NEJM in 2022 — studied tirzepatide, the newer dual agonist (GIP+GLP-1). The lipid results were even more striking:

Tirzepatide's stronger LDL reduction is likely related to its dual receptor activity (GIP and GLP-1) and its larger weight loss — up to 20.9% of body weight at the highest dose.

SELECT trial — the cardiovascular outcome

The SELECT trial (Lincoff et al., NEJM 2023) followed 17,604 overweight adults with established cardiovascular disease for up to four years. Semaglutide 2.4 mg reduced the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% compared with placebo. The improvement in lipid profile — particularly the triglyceride reduction — is considered one of the contributing mechanisms behind this heart-protective effect.

GLP-1 and statins — should I stop my cholesterol medication?

The short answer is: no, do not stop your cholesterol medication without talking to your doctor.

Statins (such as atorvastatin, rosuvastatin, and simvastatin) and GLP-1 medications work through different pathways and are complementary, not competing. Statins primarily lower LDL by inhibiting the liver's cholesterol production, while GLP-1 medications primarily reduce triglycerides and VLDL production. The combination can deliver a better overall lipid profile than either medication alone.

Furthermore, statins have an extremely well-established track record of reducing cardiovascular events in people with existing heart disease — an effect that is stronger and more consistent than GLP-1 medications alone have demonstrated so far. Stopping your statin abruptly risks a rebound rise in LDL.

Talk to your doctor if you are wondering about adjusting your cholesterol medications. It may be sensible to retest your lipid profile after 3–6 months on GLP-1 medication and then discuss whether your statin dose needs revisiting.

Who benefits most?

The lipid benefit is generally present for everyone using GLP-1 medications, but is greatest for:

If your lipid levels are already in a healthy range, improvements will be more modest — but still present.

Practical advice

Sources